Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy

References

• Farber RS, Kerrigan JR The multiple indications for growth hormone treatment of pediatric patients. Pediatr Ann 2006;35(12):926–932. [published Online First: 2007/01/24].17236440
   PubMedGoogle Scholar
• Haverkamp F, Johansson L, Dumas H, et al. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice. Clin Ther 2008;30(2):307–316. [published Online First: 2008/03/18]. doi: 10.1016/j.clinthera.2008.02.01718343269
   PubMed Web of Science ®Google Scholar
• Spandonaro F, Cappa M, Castello R, Chiarelli F, Ghigo E, Mancusi L The impact of real practice inappropriateness and devices’ inefficiency to variability in growth hormone consumption. J Endocrinol Invest 2014;37(10):979–990. [published Online First: 2014/08/12]. doi: 10.1007/s40618-014-0138-x25103591
   PubMedGoogle Scholar
• Dahlgren J Easypod: a new electronic injection device for growth hormone. Expert Rev Med Devices 2008;5(3):297–304. [published Online First: 2008/05/03]. doi: 10.1586/17434440.5.3.29718452378
   PubMed Web of Science ®Google Scholar
• Koledova K, Stoyanov G, Yao M, et al. Analysis of results from the global, 5-year Easypod™ Connect Observational Study (ECOS) study in children with growth disorders. 10th International Meeting for Pediatric Endocrinology Washington, DC; 2017.
   Google Scholar
• Koledova E, Stoyanov G, Ovbude L, Davies PSW Adherence and long-term growth outcomes: results from the Easypod™ connect observational study (ECOS) in paediatric patients with growth disorders. Endocr Connect 2018;7(8):914–923. [published Online First: 2018/10/10]. doi: 10.1530/EC-18-017229976785
   PubMedGoogle Scholar
• Cacciari E, Milani S, Balsamo A, et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 2006;29(7):581–593. [published Online First: 2006/09/08]. doi: 10.1007/bf0334415616957405
   PubMed Web of Science ®Google Scholar
• Greulich W, Pyle S Radiographic Atlas of Skeletal Development of the Hand and Wrist. 2nd ed: Stanford University Press, United States 1959.
   Google Scholar
• Maggio MC, Vergara B, Porcelli P, et al. Improvement of treatment adherence with growth hormone by easypod device: experience of an Italian centre. Ital J Pediatr 2018;44(1):113 [published Online First: 2018/09/29]. doi: 10.1186/s13052-018-0548-z30261918
   PubMedGoogle Scholar
• Bang P, SF A, Argente J, et al. Identification and management of poor response to growth-promoting therapy in children with short stature. Clinical Endocrinology 2012;77(2):169–181. [published Online First: 2012/05/01]. doi: 10.1111/j.1365-2265.2012.04420.x22540980
   PubMedGoogle Scholar
• Bagnasco F, Di Iorgi N, Roveda A, Gallizia A, Haupt R, Maghnie M Prevalence and correlates of adherence in children and adolescents treated with growth hormone: a multicenter Italian study. Endocr Pract 2017;23(8):929–941. [published Online First: 2017/06/15]. doi: 10.4158/ep171786.or28614005
   PubMed Web of Science ®Google Scholar
• Lass N, Reinehr T Low treatment adherence in pubertal children treated with thyroxin or growth hormone. Horm Res Paediatr 2015;84(4):240–247. [published Online First: 2015/08/19]. doi: 10.1159/00043730526279278
   PubMedGoogle Scholar
• Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH research society. GH research society. J Clin Endocrinol Metab 2000;85(11):3990–3993. [published Online First: 2000/11/30]. doi: 10.1210/jcem.85.11.698411095419
   PubMed Web of Science ®Google Scholar
• Ranke MB, Lindberg A Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab 2010;95(3):1229–1237. [published Online First: 2010/01/26]. doi: 10.1210/jc.2009-147120097713
   PubMedGoogle Scholar
• Cutfield WS, Derraik JG, Gunn AJ, et al. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One 2011;6(1):e16223 [published Online First: 2011/02/10]. doi: 10.1371/journal.pone.001622321305004
   PubMed Web of Science ®Google Scholar
• Saz-Parkinson Z, Granados MS, Amate Blanco JM Study of Adherence to Recombinant Growth Hormone Treatment of Children with a GH Deficiency: Contributions to Treatment Control and Economic Impact. Madrid: Agencia de Evaluación de Tecnologías Sanitarias (AETS) Instituto de Salud Carlos III; 2013.
   Google Scholar
• Pitukcheewanont P, Desrosiers P, Steelman J, et al. Issues and trends in pediatric growth hormone therapy – an update from the GHMonitor observational registry. Pediatr Endocrinol Rev 2008;5 Suppl 2:702–707. [published Online First: 2008/05/28].18317441
   PubMedGoogle Scholar
• Elashmawy AA, Anwar GM, Elsedfy H, et al. Cost-effectiveness of EasypodTM device versus other somatotropin delivery techniques in Egypt in treatment of growth hormone deficiency. Value Health 2017;20(9):A586. doi: 10.1016/j.jval.2017.08.1062
   PubMed Web of Science ®Google Scholar
• Vitova V, Tichopad A Cost-effectiveness of somatropin administration with increased adherence due to monitoring compared to non-monitored administration in patients with growth hormone deficiency. Value Health 2013;16(7):A622–A623. doi: 10.1016/j.jval.2013.08.1825
   Web of Science ®Google Scholar
• Capri S, Ceci A, Terranova L, Merlo F, Mantovani L Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Inf J 2001;35(1):189–201. doi:10.1177/009286150103500122
   Google Scholar
• Loche S, Salerno M, Garofalo P, et al. Adherence in children with growth hormone deficiency treated with r-hGH and the easypod device. J Endocrinol Invest 2016;39(12):1419–1424. [published Online First: 2016/07/14]. doi: 10.1007/s40618-016-0510-027406716
   PubMedGoogle Scholar
• Ranke MB, Lindberg A, Chatelain P, et al. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS international board. Kabi pharmacia international growth study. J Clin Endocrinol Metab 1999;84(4):1174–1183. [published Online First: 1999/04/13]. doi: 10.1210/jcem.84.4.563410199749
   PubMedGoogle Scholar